OBJECTIVES: Patients with advanced squamous cell carcinoma of the head and neck (SCCHN) have limited treatment options. Inhibition of histone deacetylases (HDACs) represents a novel therapeutic approach warranting additional investigation in solid tumors. METHODS: A phase II trial of single agent romidepsin, an HDAC inhibitor, was performed in 14 patients with SCCHN who provided consent for pre- and post-therapy samples of accessible tumor, blood and uninvolved oral mucosa. Romidepsin was administered at 13 mg/m(2) as a 4-h intravenous infusion on days 1, 8 and 15 of 28 day cycles, with response assessment by RECIST every 8 weeks. RESULTS: Objective responses were not observed, although 2 heavily pretreated patients had brief clinical disease stabilization. Observed toxicities were expected, including frequent severe fatigue. Immunohistochemical analysis of 7 pre- and post-treatment tumor pairs demonstrated induction of p21(Waf1/Cip1) characteristic of HDAC inhibition, as well as decreased Ki67 staining. Exploratory microarray analyses of mucosal and tumor samples detected changes in gene expression following romidepsin treatment that were most commonly associated with regulation of transcription, cell cycle control, signal transduction, and electron transport. Treatment with romidepsin did not alter the extent of DNA methylation of candidate gene loci (including CDH1 and hMLH1) in SCCHN tumors. CONCLUSIONS: Single agent romidepsin has limited activity for the treatment of SCCHN but can effectively achieve tumor-associated HDAC inhibition. Although tolerability of romidepsin in this setting may be limiting, further evaluation of other HDAC inhibitors in combination with active therapies may be justified.
OBJECTIVES:Patients with advanced squamous cell carcinoma of the head and neck (SCCHN) have limited treatment options. Inhibition of histone deacetylases (HDACs) represents a novel therapeutic approach warranting additional investigation in solid tumors. METHODS: A phase II trial of single agent romidepsin, an HDAC inhibitor, was performed in 14 patients with SCCHN who provided consent for pre- and post-therapy samples of accessible tumor, blood and uninvolved oral mucosa. Romidepsin was administered at 13 mg/m(2) as a 4-h intravenous infusion on days 1, 8 and 15 of 28 day cycles, with response assessment by RECIST every 8 weeks. RESULTS: Objective responses were not observed, although 2 heavily pretreated patients had brief clinical disease stabilization. Observed toxicities were expected, including frequent severe fatigue. Immunohistochemical analysis of 7 pre- and post-treatment tumor pairs demonstrated induction of p21(Waf1/Cip1) characteristic of HDAC inhibition, as well as decreased Ki67 staining. Exploratory microarray analyses of mucosal and tumor samples detected changes in gene expression following romidepsin treatment that were most commonly associated with regulation of transcription, cell cycle control, signal transduction, and electron transport. Treatment with romidepsin did not alter the extent of DNA methylation of candidate gene loci (including CDH1 and hMLH1) in SCCHN tumors. CONCLUSIONS: Single agent romidepsin has limited activity for the treatment of SCCHN but can effectively achieve tumor-associated HDAC inhibition. Although tolerability of romidepsin in this setting may be limiting, further evaluation of other HDAC inhibitors in combination with active therapies may be justified.
Authors: Bertrand Coiffier; Barbara Pro; H Miles Prince; Francine Foss; Lubomir Sokol; Matthew Greenwood; Dolores Caballero; Peter Borchmann; Franck Morschhauser; Martin Wilhelm; Lauren Pinter-Brown; Swaminathan Padmanabhan; Andrei Shustov; Jean Nichols; Susan Carroll; John Balser; Barbara Balser; Steven Horwitz Journal: J Clin Oncol Date: 2012-01-23 Impact factor: 44.544
Authors: Susan E Bates; Zhirong Zhan; Kenneth Steadman; Tomasz Obrzut; Victoria Luchenko; Robin Frye; Robert W Robey; Maria Turner; Erin R Gardner; William D Figg; Seth M Steinberg; Alex Ling; Tito Fojo; Kin Wah To; Richard L Piekarz Journal: Br J Haematol Date: 2009-10-28 Impact factor: 6.998
Authors: Richard L Piekarz; Robin Frye; H Miles Prince; Mark H Kirschbaum; Jasmine Zain; Steven L Allen; Elaine S Jaffe; Alexander Ling; Maria Turner; Cody J Peer; William D Figg; Seth M Steinberg; Sonali Smith; David Joske; Ian Lewis; Laura Hutchins; Michael Craig; A Tito Fojo; John J Wright; Susan E Bates Journal: Blood Date: 2011-02-25 Impact factor: 22.113
Authors: Suresh S Ramalingam; Michael L Maitland; Paul Frankel; Athanassios E Argiris; Marianna Koczywas; Barbara Gitlitz; Sachdev Thomas; Igor Espinoza-Delgado; Everett E Vokes; David R Gandara; Chandra P Belani Journal: J Clin Oncol Date: 2009-11-23 Impact factor: 44.544
Authors: Kela Liu; Huaiyun Huang; Perkins Mukunyadzi; James Y Suen; Ehab Hanna; Chun-Yang Fan Journal: Otolaryngol Head Neck Surg Date: 2002-05 Impact factor: 3.497
Authors: Theodoros N Teknos; J Grecula; A Agrawal; M O Old; E Ozer; R Carrau; S Kang; J Rocco; D Blakaj; V Diavolitsis; B Kumar; P Kumar; Q Pan; M Palettas; L Wei; R Baiocchi; P Savvides Journal: Invest New Drugs Date: 2018-12-19 Impact factor: 3.850